Latest Regulatory Engagement News

Page 1 of 24
An independent interim analysis has confirmed statistically significant iPPS benefits in Paradigm’s rest-of-world knee osteoarthritis cohort, giving the company a possible route to continue development despite the overall trial failing its futility test. Any new trial remains subject to funding, creditor approval and regulatory discussions.
Ada Torres
Ada Torres
19 Nov 2026
Neurizon’s first participant in the 250-person Regimen I ALS trial has completed the 36-week randomised phase and entered an optional active treatment extension. The milestone keeps the program on track for topline results in late Q2 2027, while recent FDA feedback points to a potential single-trial approval pathway if the data meet regulatory standards.
Ada Torres
Ada Torres
13 Nov 2026
Smart Parking has posted record FY26 revenue of $126.0 million and adjusted EBITDA of $30.8 million, while setting a target of 3,000 ANPR sites by December 2028. The next phase will require the company to turn US investment, acquisitions and regulatory progress into sustained site growth.
Victor Sage
Victor Sage
13 Nov 2026
Ceretas has enrolled the first patient in its Phase 2 CERE-CALM Alzheimer’s trial after completing its first quarter as an ASX-listed company. The medical technology group ended September with $7.1 million in cash, while a device milestone unlocked a further $692,578 in non-dilutive funding.
Victor Sage
Victor Sage
30 Oct 2026
BlinkLab has reported 82% sensitivity and 83% specificity from an exploratory ADHD study in 208 children, while preparing a US regulatory program for a second product. Its autism diagnostic remains on track for pivotal study completion this quarter, with A$16.2 million in cash at 30 September.
Victor Sage
Victor Sage
29 Oct 2026
Greenwing Resources has progressed DLE testing at its San Jorge lithium project and pushed its Que River pre-feasibility study into early 2027. But with A$1.807 million in cash and an estimated 1.6 quarters of funding at current outflows, project progress remains tied to new financing or strategic deals.
Maxwell Dee
Maxwell Dee
28 Oct 2026
Paradigm has reported a strong pain and function signal for iPPS outside the US, including a 1.105-point advantage over placebo at Day 112. The result does not revive the halted Phase 3 trial, with the company under administration and a potential funding proposal still unreceived.
Ada Torres
Ada Torres
15 Oct 2026
LTR Pharma has completed the final Phase II pharmacokinetic report for SPONTAN, confirming a median 10-minute time to peak concentration against 60 minutes for an oral vardenafil tablet. The result completes the FDA-aligned dataset ahead of planned US submission work, although efficacy in erectile dysfunction patients remains to be tested.
Victor Sage
Victor Sage
1 Oct 2026
Magnetite Mines has warned that its existing cash is insufficient to fund planned activities for the next 12 months, while auditors highlighted a material uncertainty over the company’s ability to continue as a going concern. The ASX-listed miner is cutting costs and reshaping Razorback around a lower-capital development pathway.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Vectus Biosystems swung to a $1.56 million FY2026 profit, but the result was driven largely by the sale of its VB4-P5 compound for XORTX shares and warrants rather than recurring operations. The company is now directing its resources towards VB0004 while its auditor flags material uncertainty over ongoing funding.
Ada Torres
Ada Torres
18 Sept 2026
Jameson Resources is raising up to A$5 million through a discounted entitlement offer to complete environmental approvals and Indigenous partnerships for its Crown Mountain steelmaking coal project.
Maxwell Dee
Maxwell Dee
2 Sept 2026
Ceretas Limited posted a $1.63 million net loss for FY26 on $1.28 million revenue from government grants, advancing its clinical-stage Alzheimer’s ultrasound platform. The company completed an $8 million IPO in July to fund pivotal trials and device development.
Ada Torres
Ada Torres
31 Aug 2026

Browse the archive

Full archive